

MicroRNA for Personalized Medicine

#### Gabriele Grunig, DVM, PhD & Serhiy Pylawka




### Problem

Up to 50 million people worldwide are estimated to be affected by pulmonary hypertension (PH)

- On average, 2 years from start of symptoms to diagnosis
- 5 categories of PH (WHO class I–WHO class V), heterogeneity within each category
- No cure for PH for any of the categories
- Without treatment, life expectancy of 2 years for some forms of PH
- Decreased quality of life for all forms of PH


**Analytics**<sup>IM</sup>



#### Are You Pulmonary Hypertension Aware? | Pulmonary Hypertension News

Released on May 5 to mark World Pulmonary Hypertension Awareness Day, this video from Buns and Pearls goes over some of the basic facts about the...


PULMONARYHYPERTENSIONNEWS.COM



# **Our Solution**

#### MicroRNA-based Diagnostics


- Can help to identify the molecular cause of pulmonary hypertension
- Have diagnostic and predictive power
- Can aid in: Tracking the course of Pulmonary Hypertension
  - Matching the patient to the optimal drug
  - Clinical trials of new drugs (match patient to drug / detect responses)
- Are minimally invasive
- MicroRNAs
  - Small non-coding RNA
  - Stable in body fluids (plasma, serum)
  - Conserved across different species





### **Team Mirna Analytics**

m RNA Analytics™



Serhiy Pylawka, MS – co-Founder, Test Development & Business Development

Gabriele Grunig, DVM, PhD – co-Founder, Collaborations, Test Development & Business Development

#### Addition Sought to the Team Mirna Analytics

Pulmonary Hypertension

#### Fundraising for Optimization of Diagnostic

**Bring to Market** 

Diagnostic miRNA —

test



#### **Global Estimates:**

Therapeutics Market: \$50 B (\$10,000 per patient, 50 M) Diagnostics Market: \$5 B (\$1,000 per patient, 50 M)



# Thank you !!





New York City Economic Development Corporation



